Conditions: Opioid-Induced Bowel Dysfunction
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 439
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction.

Detailed description:

Arms:
arm 1: Lubiprostone: 24 mcg capsule twice daily (BID) for 36 weeks

Interventions: intervention 1: Lubiprostone 24
Intervention descriptions: intervention 1: 24 mcg capsules for oral administration

Protocol document: